title: Clinical results of the application of perftoran for the treatment of odontogenous abcesses and phlegmons in the maxillofacial region.
abstract: BACKGROUND
  The study was carried out to ascertain the effects of perftoran in the treatment of facial and Dupuytren's phlegmons with simultaneous estimation of the general reaction in humans.
  
  
  METHODS
  Seventy-six patients with facial or Dupuytren's phlegmons were divided into 2 groups, one with mild and the other with a severe course of the inflammatory process. Each group was subdivided into 2 subgroups: one control group with "traditional" treatment and one study group where the traditional treatment was supplemented with perftoran. Perftoran was given to both study groups (1-3 ml/kg body weight, single intravenous injection) immediately after surgery plus further daily local wound treatment with perftoran until the end of exudation. The condition of the purulent wound and its reparative processes, the state of free-radical oxidation processes, antihypoxia and effects of perftoran were evaluated at various treatment stages (the moment of surgically opening the phlegmon, on the 1st, 3rd and 7th postoperative days).
  
  
  RESULTS
  Perftoran considerably decreased the tissue hypoxia as well as the transaminase and creatinine levels in blood serum. Perftoran helped to decrease the intoxication indices, hypoxaemia by 10-15%, to speed local wound healing by 2-5 days and to shorten the time of hospital treatment by 3-6 days on average.
  
  
  CONCLUSIONS
  The many positive effects of perftoran on the clinical course of the disease and on a series of homeostatic parameters allow us to recommend that this drug to be added for treating patients having odontogenous phlegmons in the maxillofacial region.
authors: Nizhny Novgorod State Medical Academy (Chairperson: Prof. Vyacheslav V. Shkarin), Russia.
authors: Evgenia Alexandrovna
authors: EA
authors: Durnovo
authors: Nizhny Novgorod State Medical Academy (Chairperson: Prof. Vyacheslav V. Shkarin), Russia.
authors: Irina Vladimirovna
authors: IV
authors: Furman
authors: SPF "Perftoran" (Chairperson: Sergey Yurievitch Pushkin), Pushchino, Moscow Region, Russia.
authors: Sergey Yurievitch
authors: SY
authors: Pushkin
authors: SPF "Perftoran" (Chairperson: Sergey Yurievitch Pushkin), Pushchino, Moscow Region, Russia.
authors: Igor Alexeevitch
authors: IA
authors: Maslennikov
authors: SPF "Perftoran" (Chairperson: Sergey Yurievitch Pushkin), Pushchino, Moscow Region, Russia. Electronic address: perftoran@yandex.ru.
authors: Olga Grigorievna
authors: OG
authors: Bondar
authors: Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences (Chairperson: Genrih Romanovitch Ivanitsky), Pushchino, Moscow Region, Russia.
authors: Genrih Romanovitch
authors: GR
authors: Ivanitsky
mesh_terms: D000038:Abscess / Q000188:drug therapy / Q000601:surgery*; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D001802:Blood Substitutes / Q000008:administration & dosage / Q000627:therapeutic use*; D002481:Cellulitis / Q000188:drug therapy / Q000601:surgery*; D003404:Creatinine / Q000097:blood; D005145:Face / Q000601:surgery*; D005260:Female; D005466:Fluorocarbons / Q000008:administration & dosage / Q000627:therapeutic use*; D005491:Focal Infection, Dental / Q000188:drug therapy / Q000601:surgery*; D005609:Free Radicals / Q000378:metabolism; D006801:Humans; D000860:Hypoxia / Q000517:prevention & control; D007275:Injections, Intravenous; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D012189:Retrospective Studies; D000637:Transaminases / Q000097:blood; D016896:Treatment Outcome; D014945:Wound Healing / Q000502:physiology
chemical_list: D001802:Blood Substitutes; D005466:Fluorocarbons; D005609:Free Radicals; C063334:perftoran; D003404:Creatinine; D000637:Transaminases